#TempusAI
#AIAct #CatturaRegolatoria #TempusAI
September 25, 2026 at 4:52 AM
at all, and whether the next wave of AI challengers will come from startups or only from companies that can pay for a compliance department.

#AIAct #RegulatoryCapture #TempusAI
September 25, 2026 at 4:50 AM
et si la prochaine vague de challengers de l'IA viendra des start-up ou seulement d'entreprises capables de financer un service de conformité. #AIAct #CaptureRéglementaire #TempusAI
September 25, 2026 at 4:51 AM
darf – und ob die nächste Welle von KI-Herausforderern von Start-ups kommt oder nur von Unternehmen, die sich eine Compliance-Abteilung leisten können. #AIAct #RegulatoryCapture #TempusAI
September 25, 2026 at 4:51 AM
ImmunoDriver-1: Driver alterations (dAlts) and their immunological implications in early and metastatic non-small cell lung cancer (NSCLC) - Lee et al. @UCLAHealth @TempusAI #ASCO25 Abst 8060
meetings.asco.org/abstracts-pr... #lcsm #ImmunoOnc #PrecisionMedicine
May 22, 2025 at 11:59 PM
La cuestión ahora es si el reglamento europeo acabará decidiendo quién puede siquiera competir, y si la próxima ola de aspirantes en IA vendrá de startups o solo de empresas que puedan pagarse un departamento de cumplimiento. #AIAct #CapturaRegulatoria #TempusAI
September 25, 2026 at 4:52 AM
Clinicogenomic landscape and outcomes of metastatic colorectal cancer patients with pathogenic GNAS variants - @polanimd et al. #ASCO25 Abst 3572 meetings.asco.org/abstracts-pr... @TempusAI #crcsm #PrecisionMedicine
May 23, 2025 at 12:39 PM
🐋 Whale Alert: $1.8M single-candle premium in #$TEM 115 Calls (exp 1/15/27) — option price ripped +21.49% to $5.63 on a late-day volume spike 📈🔥. Unlike recent sweeps, this one actually spans Nov 3 earnings — a real earnings-inclusive bullish bet, not a pre-report play. @TempusAI
NOT FINANCIAL ADVICE
September 24, 2026 at 7:22 PM
GEMINI-NSCLC study: Integrated longitudinal multi-omic biomarker profiling study of non-small cell lung cancer (NSCLC) patients - Palmer et al. #ASCO25 Abst TPS8114 meetings.asco.org/abstracts-pr... @TempusAI @AstraZeneca #LiquidBiopsy #ImmunoOnc #oncorad
May 23, 2025 at 2:13 PM
Outcomes for patients with SPOP-mutated castration-resistant prostate cancer (CRPC) treated with an androgen receptor pathway inhibitor (ARPI) - Park et al. #ASCO25 Abst e17085 meetings.asco.org/abstracts-pr... @TempusAI #pcsm
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
May 23, 2025 at 2:06 PM
Transcriptomic biomarkers of therapeutic response to antibody-drug conjugates in metastatic breast cancer: A comprehensive multi-center study - @AlkassisSamer et al. #ASCO25 Abst 1041
meetings.asco.org/abstracts-pr... @TempusAI #bcsm #caxtx
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
May 23, 2025 at 1:13 PM
February 28, 2025 at 4:36 PM
Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines [May 20, 2022] Yap et al. @JAMANetworkOpen jamanetwork.com/journals/jam... #PrecisionMedicine #geneticcounselors #blcsm #lcsm @TempusAI
Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines
This cross-sectional study examines the prevalence of germline findings in patients undergoing tumor/normal matched sequencing among cancer types lacking guidelines.
jamanetwork.com
January 30, 2025 at 2:54 PM
Cathie Wood @CathieDWood
strikes again! ARK’s May 6 trades: Massive buys in #$TEM @TempusAI
(AI precision medicine) & #$NTLA @intelliatx
(CRISPR) across ARKK/ARKG. Trimmed #$TWST @TwistBioscience
& #$AMD to fuel the fire.
doubling down on AI × Genomics revolution! #ARKTrades #CathieWood
May 7, 2026 at 3:37 AM
Circulating tumor DNA (ctDNA) dynamics in liver-limited metastatic colorectal cancer (mCRC) patients resected after first-line systemic treatment - @VStudiale et al. @AoupPisana @TempusAI #ASCO25 Abst 3544
meetings.asco.org/abstracts-pr... #crcsm #MRD #LiquidBiopsy #PrecisionMedicine
May 23, 2025 at 1:55 PM
🚀 Tempus AI is on the move! Shares are jumping after the FDA cleared its next-gen RNA cancer test, a breakthrough that could speed new cancer drug trials and unlock major biotech partnerships.

#TempusAI #Stocks #Biotech #FDA #HealthTech #Investing

evolutionaihub.com/tempus-ai-st...
Tempus AI Stock Jumps As FDA Clears New Cancer-Testing Device
Tempus AI stock surges after FDA clears its new RNA cancer-testing device, opening fresh commercial opportunities and boosting investor confidence.
evolutionaihub.com
September 22, 2025 at 3:52 PM
📊 TRADE IDEA FOR Tuesday (10/07/2025): - AI

🔹 $CRVW PIVOT: 132.91 #CRVW #CrownVehicle
🔹 $PLTR PIVOT: 180.21 #PLTR #Palantir
🔹 $AISP PIVOT: 2.920 #AISP #AirshipAI
🔹 $CRWD PIVOT: 490.11 #CRWD #CrowdStrike
🔹 $AI PIVOT: 19.59 #AI #C3ai
🔹 $TEM PIVOT: 92.43 #TEM #TempusAI
.....
October 8, 2025 at 1:09 PM
Watch out investors, she's on the prowl again. Please remember, you are not safe because you share her faith.

One day in on her spree, she's on track to break her own record of a terrible track record:

www.fool.com/investing/20...

#TSLA #AMD #TempusAI #Tesla #ARKK
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought | The Motley Fool
The widely followed growth investor keeps making moves.
www.fool.com
February 6, 2026 at 2:32 AM
Discover the Top 5 AI tools every medical oncologist should know for accurate diagnosis and treatment of cancer patients.

@Path_AI, #IBMWatson, #GoogleHealthAI, @TempusAI, @GoogleDeepMind

Connect with top medical oncologists-
Oncology Email List
Reliable Oncology Email List Do you want to market your products or services to leading oncology professionals? Now you can connect with more than 35,000 verified contacts in LogiChannel's Oncology…
bit.ly
August 19, 2025 at 7:01 PM

Bluesky's Top 10 Trending Words (past 10min):
💨x40 - cleveland
💨x31 - babylon
💨x18 - clouding
💨x14 - showgirl
💨x1* - iran 🔓
💨x1* - ukraine 🔓
💨x13 - 1﹐924
💨x11 - antisemitismus
💨x10 - efi
💨x9 - xi
*🔓 = Unlocked Emergency Words (see img)

#йобанарусня 🇺🇦

(Something not right? Reply!)
September 25, 2026 at 5:00 AM
Friday breaking news 💥

“@TempusAI Announces the Acquisition of @paige_ai, with its strong foundation in #pathology and #AI is rooted in its proprietary dataset of almost 7 million digitized pathology slides that are clinically annotated”

www.tempus.com/news/tempus-...
Tempus Announces the Acquisition of Paige - Tempus
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acquisition of Paige, an AI company specializing in digital pathology....
www.tempus.com
August 22, 2025 at 4:16 PM
📢 个性化癌症疫苗取得突破,带动肿瘤测序需求升温,相关诊断公司成为资本市场新焦点。Moderna与Merck的积极试验结果推高TempusAI等股价,也引发Personalis潜在竞购战。市场同时看好MRD检测的长期空间,但行业仍面临临床、商业化及竞争等不确定性。...
“个性化癌症疫苗”突破!“肿瘤测序”站上风口 | 文学城
www.wenxuecity.com
September 6, 2026 at 10:50 PM
Tempus AI (#$TEM) rose 47% on a Merck and Moderna trial. Two analysts upgraded it after the run. #TempusAI
Tempus AI (TEM) stock: $80 Cantor target after 47% run
Cantor Fitzgerald started Tempus AI (TEM) at overweight with an $80 target. The 47% August run came from a Merck and Moderna trial, not from Tempus.
aistockwire.com
September 3, 2026 at 2:12 PM
two years after graduating college, and with no plan to do anything in music, country-pop sensation Stella Lefkosky, daughter of Groupon/TempusAI billionaire, wrote a hit song about... Boston.

hearing her idea of "working hard" involves thinking & writing posts on social media... umm...
September 2, 2026 at 7:36 PM
#Tempus AI (#$TEM) just turned its first profit. Its stock is still half off its high. #TempusAI
Tempus AI (TEM) stock: what it does, who owns it, bear case
A deep dive on Tempus AI (TEM): what the cancer-data company does, its first profit, who controls it, the Spruce Point short report, and the Pelosi trade.
aistockwire.com
August 16, 2026 at 11:45 PM